EW Edwards Lifesciences Corporation Common Stock

NYSE · Health Care · Wyświetl na SEC EDGAR ↗
$92,49
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 4, 2026
Zakres 52 tyg.
$72–$96
84% of range
Ocena Analityków
BUY
40 analysts
Cena Docelowa
$101
+9% upside
P/E (TTM)
57.4
ROE
10.6%
Marża Zysku Netto
17.7%

O Edwards Lifesciences Corporation Common Stock Przegląd firmy z Wikipedii

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

Czytaj więcej

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

History

Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.

Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.

Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.

In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.

On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.

Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.

In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.

In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.

In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.

In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.

In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.

In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.

In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.

In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.

In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.

In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.

Business segments

Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).

Transcatheter Heart Valve

The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.

Transcatheter Mitral and Tricuspid Therapies

The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.

Surgical

The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.

Critical Care

Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.

Organizational culture

Edwards Lifesciences Foundation

The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.

Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.

Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗

Wikidata ↗

EW Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy

Cena
$92.49
Kapitalizacja Rynkowa
$61.04B
P/E (TTM)
57.4
EPS (TTM)
$1.83
Przychody (TTM)
$6.07B
Stopa dywidendy
—
ROE
10.6%
D/E Dług/Kapitał
0.1
Zakres 52 tyg.
$72 – $96

EW Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok

Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS

Przychody i Zysk Netto $6.07B
10-point trend, +104.7%
2016-12-31 → 2025-12-31
EPS $1.83
10-point trend, -29.9%
2016-12-31 → 2025-12-31
Wolny przepływ pieniężny $1.33B
10-point trend, +152.7%
2016-12-31 → 2025-12-31
Marże 17.7%
10-point trend, +6.7%
2016-12-31 → 2025-12-31

Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza
P/E (TTM)
5-point trend, -14.4%
57.4
26.3
P/S (TTM)
5-point trend, -47.2%
10.1
4.4
P/B
5-point trend, -65.4%
5.9
5.3
EV / EBITDA
5-point trend, -26.3%
40.4
—
Price / FCF (Cena / FCF)
5-point trend, -35.5%
45.7
—

Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza
Gross Margin (Marża brutto)
5-point trend, +2.5%
78.0%
63.1%
Operating Margin (Marża Operacyjna)
5-point trend, -35.5%
20.8%
—
Net Profit Margin (Marża Zysku Netto)
3-point trend, -24.2%
17.7%
15.6%
ROA
3-point trend, -49.5%
8.0%
7.6%
ROE
3-point trend, -53.1%
10.6%
15.0%
ROIC
5-point trend, -58.7%
9.6%
—

Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
5-point trend, -43.3%
0.1
—
Current Ratio (Wskaźnik bieżący)
5-point trend, +20.6%
3.7
1.7
Quick Ratio (Wskaźnik Szybkości)
5-point trend, +35.7%
2.7
—

Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza
Revenue YoY (Przychody R/R)
5-point trend, +16.0%
11.6%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
5-point trend, +16.0%
10.8%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
5-point trend, +16.0%
6.7%
—
EPS YoY
5-point trend, -23.1%
-73.7%
—
Net Income YoY (Zysk Netto R/R)
5-point trend, -28.6%
-74.3%
—

Wskaźniki na akcję EPS, wartość księgowa na akcję, przepływy pieniężne na akcję, dywidenda na akcję

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza
EPS (Diluted) (EPS (Rozwodniony))
5-point trend, -23.1%
$1.83
—

Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności

Wskaźnik
Trend 5-letni
EW
Mediana porównawcza

EW Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu

KUP 40 analityków
  • Mocne kupno 13 32,5%
  • Kup 17 42,5%
  • Trzymaj 10 25,0%
  • Sprzedaj 0 0,0%
  • Mocna sprzedaż 0 0,0%

12-miesięczny cel cenowy

26 analityków · 2026-08-19
Średni cel $101.50 +9,7%
Średnia cel $100.96 +9,2%

Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników

Średnie zaskoczenie
0.02%
Okres EPS Actual EPS Szacowany Niespodzianka
30 czerwca 2026 $0.78 $0.76 0.02%
31 marca 2026 $0.78 $0.75 0.03%
31 grudnia 2025 $0.58 $0.64 -0.06%
30 września 2025 $0.67 $0.61 0.06%
30 czerwca 2025 $0.67 $0.64 0.03%
31 marca 2025 $0.64 $0.61 0.03%

Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora

Ticker Kapitalizacja Rynkowa P/E Przychody r/r Marża Netto ROE Marża brutto
EW $49.50B 46.6 11.6% 17.7% 10.6% 78.0%
ABT $250.18B 33.7 5.7% 14.7% 13.1% —
ISRG $201.11B 72.0 20.5% 28.4% 16.7% 66.0%
SYK $134.44B 41.8 11.2% 12.9% 15.1% 64.0%
BSX — 49.1 19.9% 14.4% 12.6% 69.0%
BDX — 25.3 8.2% 7.7% 6.5% —
IDXX $53.93B 51.7 10.4% 24.6% 69.2% 61.8%
DXCM $25.54B 31.8 15.6% 17.9% 31.4% 60.1%
GEHC — 18.0 4.8% 10.1% 22.1% 40.0%
RMD $28.11B 18.7 9.8% 26.9% 23.6% 61.1%
ZBH $28.66B 25.3 7.2% 8.6% 5.6% —

Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne

Rachunek zysków i strat 17
Dane roczne Rachunek zysków i strat dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +161.2% $6.07B $5.44B $5.01B $4.46B $5.23B $4.39B $4.35B $3.72B $3.44B $2.96B $2.49B $2.32B
Cost of Revenue 12-point trend, +113.3% $1.33B $1.12B $978M $724M $1.25B $1.08B $1.11B $939M $875M $797M $617M $626M
Gross Profit 12-point trend, +178.9% $4.73B $4.32B $4.03B $3.74B $3.98B $3.31B $3.23B $2.78B $2.56B $2.17B $1.88B $1.70B
R&D Expense 12-point trend, +211.5% $1.08B $1.05B $963M $844M $903M $761M $753M $622M $553M $442M $383M $346M
SG&A Expense 12-point trend, +143.0% $2.09B $1.79B $1.58B $1.36B $1.49B $1.23B $1.24B $1.09B $991M $905M $851M $858M
Operating Income 10-point trend, +68.3% $1.26B $1.38B $1.31B $1.50B $1.69B $898M $1.15B $748M $1.09B $751M · ·
Interest Expense 10-point trend, +2.3% · · $18M $19M $18M $16M $21M $30M $23M $19M $17M $17M
Interest Income 12-point trend, +2537.5% $169M $120M $67M $36M $17M $23M $32M $32M $20M $11M $8M $6M
Other Non-op 12-point trend, +193.5% $7M $69M $14M $5M $13M $12M $8M $4M $-1M $-5M $-4M $-8M
Pretax Income 12-point trend, +11.3% $1.27B $1.55B $1.37B $1.52B $1.70B $917M $1.17B $761M $1.03B $738M $622M $1.14B
Income Tax 12-point trend, -34.8% $217M $152M $152M $196M $199M $93M $120M $39M $451M $168M $128M $333M
Net Income 5-point trend, -28.6% $1.07B $4.17B $1.40B $1.52B $1.50B · · · · · · ·
EPS (Basic) 12-point trend, -51.7% $1.84 $6.98 $2.31 $2.46 $2.41 $1.32 $1.68 $1.15 $2.77 $2.67 $2.30 $3.81
EPS (Diluted) 12-point trend, -51.1% $1.83 $6.97 $2.30 $2.44 $2.38 $1.30 $1.64 $1.13 $2.70 $2.61 $2.25 $3.74
Shares (Basic) 12-point trend, +174.6% 584,800,000 597,700,000 606,700,000 619,000,000 623,300,000 622,600,000 624,800,000 627,600,000 210,900,000 213,000,000 215,500,000 213,000,000
Shares (Diluted) 12-point trend, +170.0% 585,800,000 599,300,000 609,400,000 624,200,000 631,200,000 631,900,000 636,700,000 640,900,000 215,900,000 217,800,000 220,300,000 217,000,000
EBITDA 12-point trend, +1971.1% $1.42B $1.53B $1.68B $1.89B $1.83B $1.00B $1.24B $826M $82M $71M $66M $69M
Bilans 29
Dane roczne Bilans dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +349.4% $2.94B $3.05B $1.13B $769M $863M $1.18B $1.18B $714M $818M $930M $718M $654M
Short-term Investments 12-point trend, +64.1% $1.29B $931M $500M $446M $604M $219M $338M $242M $519M $341M $506M $785M
Receivables 12-point trend, +129.0% $660M $609M $772M $643M $582M $515M $544M $457M $439M $366M $315M $288M
Inventory 12-point trend, +279.4% $1.13B $1.09B $904M $876M $727M $802M $641M $607M $555M $397M $340M $297M
Prepaid Expense 12-point trend, +176.6% $135M $121M $129M $110M $85M $75M $59M $54M $61M $46M $45M $49M
Other Current Assets 12-point trend, +178.8% $339M $348M $225M $196M $237M $208M $168M $132M $117M $112M $66M $122M
Current Assets 12-point trend, +202.0% $6.74B $6.29B $4.04B $3.10B $3.18B $3.09B $2.98B $2.29B $2.55B $2.24B $2.05B $2.23B
PP&E (Net) 12-point trend, +309.1% $1.81B $1.69B $1.59B $1.63B $1.55B $1.40B $1.06B $868M $680M $580M $482M $443M
PP&E (Gross) 12-point trend, +229.3% $2.66B $2.48B $2.29B $2.38B $2.20B $1.99B $1.57B $1.32B $1.09B $961M $854M $808M
Accum. Depreciation 12-point trend, +132.6% $850M $794M $699M $750M $655M $598M $512M $455M $412M $381M $372M $365M
Goodwill 12-point trend, +370.4% $1.77B $1.78B $1.15B $1.06B $1.17B $1.17B $1.17B $1.11B $1.13B $626M $628M $376M
Intangibles 12-point trend, +4721.4% $1.13B $1.18B $399M $285M $324M $331M $336M $343M $468M $205M $205M $23M
Other Non-current Assets 12-point trend, +1384.1% $730M $722M $463M $299M $111M $120M $102M $34M $109M $123M $132M $49M
Total Assets 12-point trend, +288.8% $13.70B $13.06B $9.36B $8.29B $8.50B $7.24B $6.49B $5.32B $5.67B $4.51B $4.06B $3.52B
Accounts Payable 12-point trend, +290.9% $228M $197M $187M $202M $204M $196M $180M $134M $117M $97M $64M $58M
Current Liabilities 12-point trend, +325.7% $1.81B $1.51B $1.20B $1.02B $1.03B $894M $902M $877M $1.42B $532M $476M $426M
Capital Leases 7-point trend, +40.2% $83M $79M $65M $70M $69M $73M $59M · · · · ·
Deferred Tax · · · · · · $37M · · · · ·
Other Non-current Liabilities 12-point trend, +221.8% $362M $373M $251M $218M $267M $252M $203M $150M $147M $115M $285M $113M
Total Liabilities 6-point trend, +26.2% $3.36B $2.99B $2.64B $2.49B $2.67B $2.66B · · · · · ·
Long-term Debt 3-point trend, -27.8% · · · · · · · $594M $1.04B $822M · ·
Total Debt 12-point trend, +0.0% $598M $598M $597M $596M $596M $595M $594M $594M $1.04B $822M $600M $598M
Common Stock 12-point trend, +411.0% $659M $655M $650M $646M $642M $636M $218M $215M $212M $243M $239M $129M
Retained Earnings 12-point trend, +401.1% $14.24B $13.17B $8.99B $7.59B $6.07B $4.57B $3.74B $2.69B $1.96B $3.91B $3.34B $2.84B
Treasury Stock 12-point trend, +355.5% $7.09B $6.19B $5.02B $4.14B $2.42B $1.90B $1.28B $1.02B $252M $2.50B $1.84B $1.56B
AOCI 12-point trend, -136.2% $-238M $-244M $-243M $-255M $-158M $-161M $-156M $-138M $-133M $-198M $-183M $-101M
Stockholders' Equity 12-point trend, +371.7% $10.34B $10.00B $6.65B $5.81B $5.84B $4.57B $4.15B $3.14B $2.96B $2.62B $2.50B $2.19B
Liabilities + Equity 12-point trend, +288.8% $13.70B $13.06B $9.36B $8.29B $8.50B $7.24B $6.49B $5.32B $5.67B $4.51B $4.06B $3.52B
Shares Outstanding 12-point trend, +438.7% 580,700,000 654,800,000 650,500,000 646,300,000 642,000,000 636,400,000 218,100,000 207,700,000 209,700,000 211,600,000 215,400,000 107,800,000
Przepływy pieniężne 18
Dane roczne Przepływy pieniężne dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
D&A 12-point trend, +128.3% $157M $155M $145M $140M $135M $107M $89M $77M $82M $71M $66M $69M
Stock-based Comp 12-point trend, +227.3% $158M $162M $139M $127M $109M $93M $81M $71M $62M $57M $50M $48M
Deferred Tax 12-point trend, +1.3% $-66M $-163M $-242M $-262M $-44M $-52M $10M $-21M $27M $-24M $-16M $-67M
Amort. of Intangibles 12-point trend, +0.0% $8M $6M $2M $2M $8M $5M $5M $2M $8M $8M $7M $8M
Restructuring 4-point trend, +13100000.00 $13M $33M · · · · · · · · $0 $0
Other Non-cash 3-point trend, +151.6% $273M $-3.79B $-529M · · · · · · · · ·
Operating Cash Flow 12-point trend, +56.0% $1.60B $542M $896M $1.22B $1.73B $1.05B $1.18B $927M $1.00B $704M $550M $1.02B
CapEx 12-point trend, +213.9% $260M $252M $253M $245M $326M $407M $254M $239M $168M $176M $103M $83M
Investing Cash Flow 11-point trend, -125.5% $-713M $2.31B $174M $252M $-1.72B $-531M $-596M $77M $-647M $-212M $-316M ·
Debt Issued 10-point trend, -100.0% · · $0 $0 $5M $16M $19M $688M $995M $254M $31M $226M
Net Debt Issued 10-point trend, -100.0% · · $0 $0 $5M $16M $19M $688M $995M $254M $31M $226M
Stock Repurchased 12-point trend, +196.9% $893M $1.16B $880M $1.73B $513M $625M $263M $796M $763M $662M $280M $301M
Net Stock Activity 12-point trend, -196.9% $-893M $-1.16B $-880M $-1.73B $-513M $-625M $-263M $-796M $-763M $-662M $-280M $-301M
Financing Cash Flow 11-point trend, -503.3% $-957M $-983M $-711M $-1.58B $-356M $-487M $-116M $-1.10B $-473M $-268M $-159M ·
Net Change in Cash 12-point trend, -151.1% $-119M $1.91B $375M $-95M $-333M $16M $468M $-104M $-112M $212M $65M $233M
Taxes Paid 4-point trend, +78.5% $490M $1.20B $470M · · · · · · · · $275M
Free Cash Flow 12-point trend, +42.1% $1.33B $290M $643M $974M $1.41B $647M $925M $688M $833M $528M $447M $939M
Levered FCF 10-point trend, -32.3% · · $627M $957M $1.39B $633M $906M $660M $820M $513M $433M $927M
Rentowność 8
Dane roczne Rentowność dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Gross Margin 12-point trend, +6.8% 78.0% 79.5% 77.0% 79.9% 76.1% 75.4% 74.4% 74.8% 74.5% 73.1% 75.2% 73.1%
Operating Margin 8-point trend, +3.7% 20.8% 25.4% 25.6% 32.5% 32.3% 20.5% 26.4% 20.1% · · · ·
Net Margin 3-point trend, -24.2% 17.7% 76.8% 23.4% · · · · · · · · ·
Pretax Margin 12-point trend, -57.4% 21.0% 28.5% 26.6% 32.8% 32.5% 20.9% 26.8% 20.4% 30.1% 24.9% 25.0% 49.2%
EBITDA Margin 12-point trend, +693.9% 23.4% 28.2% 28.0% 35.1% 34.9% 22.9% 28.4% 22.2% 2.4% 2.4% 2.6% 2.9%
ROA 3-point trend, -49.5% 8.0% 37.2% 15.9% · · · · · · · · ·
ROE 3-point trend, -53.1% 10.6% 50.1% 22.5% · · · · · · · · ·
ROIC 8-point trend, -49.5% 9.6% 11.7% 18.5% 23.5% 23.2% 15.6% 21.7% 19.0% · · · ·
Płynność i wypłacalność 5
Dane roczne Płynność i wypłacalność dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Current Ratio 12-point trend, -29.7% 3.7 4.2 3.4 3.0 3.1 3.5 3.3 2.6 1.8 4.2 4.3 5.3
Quick Ratio 12-point trend, -32.2% 2.7 3.0 2.0 1.8 2.0 2.1 2.3 1.6 1.3 3.1 3.2 4.0
Debt / Equity 12-point trend, -78.8% 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.4 0.3 0.2 0.3
LT Debt / Equity 12-point trend, -78.8% 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.3 0.2 0.3
Interest Coverage 6-point trend, +248.3% · · 87.2 91.1 91.9 56.8 55.4 25.0 · · · ·
Efektywność 3
Dane roczne Efektywność dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Asset Turnover 12-point trend, -39.1% 0.5 0.5 0.7 0.6 0.7 0.6 0.7 0.7 0.7 0.7 0.7 0.7
Inventory Turnover 12-point trend, -41.6% 1.2 1.1 1.4 1.3 1.6 1.5 1.8 1.6 1.8 2.2 1.9 2.1
Receivables Turnover 12-point trend, +21.6% 9.6 7.9 8.5 8.8 9.5 8.3 8.7 8.3 8.7 8.7 8.3 7.9
Na akcję 5
Dane roczne Na akcję dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Book Value / Share 12-point trend, -12.4% $17.80 $16.99 $11.06 $9.55 $9.35 $7.33 $19.84 $15.12 $14.10 $12.38 $11.62 $20.33
Revenue / Share 12-point trend, -51.6% $10.36 $9.08 $9.85 $8.62 $8.29 $6.94 $20.49 $17.43 $15.91 $13.61 $11.32 $21.41
Cash Flow / Share 12-point trend, -71.1% $2.72 $0.90 $1.47 $1.95 $2.74 $1.67 $5.56 $4.34 $4.63 $3.23 $2.50 $9.42
Cash / Share 12-point trend, -16.6% $5.06 $5.17 $1.90 $1.26 $1.38 $1.90 $5.64 $3.44 $3.90 $4.40 $3.34 $6.06
EPS (TTM) 12-point trend, -51.1% $1.83 $6.97 $2.30 $2.44 $2.38 $1.30 $1.64 $1.13 $2.70 $2.61 $2.25 $3.74
Stopy Wzrostu 8
Dane roczne Stopy Wzrostu dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -40.1% 11.6% 8.6% 12.2% -14.7% 19.3% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +137.7% 10.8% 1.3% 4.5% · · · · · · · · ·
Revenue CAGR 5Y 6.7% · · · · · · · · · · ·
EPS YoY 5-point trend, -188.8% -73.7% 203.0% -5.7% 2.5% 83.1% · · · · · · ·
EPS CAGR 3Y 3-point trend, -143.6% -9.1% 43.1% 20.9% · · · · · · · · ·
EPS CAGR 5Y 7.1% · · · · · · · · · · ·
Net Income YoY 4-point trend, -6042.4% -74.3% 197.7% -7.8% 1.2% · · · · · · · ·
Net Income CAGR 3Y 2-point trend, -127.1% -11.0% 40.6% · · · · · · · · · ·
Wycena (TTM) 14
Dane roczne Wycena (TTM) dla EW
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +161.2% $6.07B $5.44B $5.01B $4.46B $5.23B $4.39B $4.35B $3.72B $3.44B $2.96B $2.49B $2.32B
Net Income TTM 12-point trend, +357.2% $1.07B $4.17B $1.40B $1.52B $1.50B $235M $235M $235M $235M $235M $235M $235M
Market Cap 12-point trend, +2063.1% $49.50B $43.57B $45.83B $45.39B $80.85B $56.95B $16.26B $10.60B $7.88B $6.61B $5.67B $2.29B
Enterprise Value 12-point trend, +3068.5% $45.88B $40.20B $44.79B $44.77B $79.98B $56.15B $15.34B $10.24B $7.58B $6.16B $5.05B $1.45B
P/E 12-point trend, +720.7% 46.6 10.6 33.2 30.6 54.4 70.2 47.4 45.2 13.9 12.0 11.7 5.7
P/S 12-point trend, +728.1% 8.2 8.0 9.1 10.2 15.5 13.0 3.7 2.8 2.3 2.2 2.3 1.0
P/B 12-point trend, +358.5% 4.8 4.4 6.9 7.8 13.9 12.5 3.9 3.4 2.7 2.5 2.3 1.0
P / Tangible Book 6-point trend, -64.1% 6.7 6.2 9.0 10.2 18.6 18.6 · · · · · ·
P / Cash Flow 12-point trend, +1286.2% 31.0 80.4 51.2 37.3 46.7 54.0 13.8 11.4 7.9 9.4 10.3 2.2
P / FCF 12-point trend, +1422.1% 37.1 150.3 71.3 46.6 57.5 88.0 17.6 15.4 9.5 12.5 12.7 2.4
EV / EBITDA 12-point trend, +53.0% 32.3 26.2 26.7 23.7 43.8 55.9 12.4 12.4 92.5 86.5 76.7 21.1
EV / FCF 12-point trend, +2129.6% 34.4 138.7 69.7 46.0 56.9 86.7 16.6 14.9 9.1 11.7 11.3 1.5
EV / Revenue 12-point trend, +1113.0% 7.6 7.4 8.9 10.0 15.3 12.8 3.5 2.8 2.2 2.1 2.0 0.6
Earnings Yield 12-point trend, -87.8% 2.1% 9.4% 3.0% 3.3% 1.8% 1.4% 2.1% 2.2% 7.2% 8.4% 8.6% 17.6%

Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat

Rachunek zysków i strat
2025-12-312024-12-312023-12-312022-12-312021-12-31
Przychody $6.07B$5.44B$5.01B$4.46B$5.23B
Marża Brutto % 78.0%79.5%77.0%79.9%76.1%
Marża Operacyjna % 20.8%25.4%25.6%32.5%32.3%
Zysk netto $1.07B$4.17B$1.40B$1.52B$1.50B
Rozwodniony EPS $1.83$6.97$2.30$2.44$2.38
Bilans
2025-12-312024-12-312023-12-312022-12-312021-12-31
Dług / Kapitał Własny 0.10.10.10.10.1
Wskaźnik bieżący 3.74.23.43.03.1
Wskaźnik Szybkości 2.73.02.01.82.0
Przepływy pieniężne
2025-12-312024-12-312023-12-312022-12-312021-12-31
Wolny przepływ pieniężny $1.33B$290M$643M$974M$1.41B

Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów

📊

Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.

Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.

Właściciele instytucjonalni (13F) 1 444 emitenci · $30.3B łącznie · Na dzień 30 czerwca 2026

Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.

Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
Nowe pozycje Zamknięte pozycje Zwiększone Zmniejszony Zmiana liczby akcji netto
154 (+9 vs poprzedni kw.) 97 (-10 vs poprzedni kw.) 459 (+10 vs poprzedni kw.) 456 (+6 vs poprzedni kw.) +26.4M

Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.

Instytucja Wartość Akcje % z śledzonych 13F Typ
VANGUARD CAPITAL MANAGEMENT LLC $3 402 739 018 37 615 952 11,25% Akcje
VANGUARD PORTFOLIO MANAGEMENT LLC $2 389 175 425 26 411 402 7,90% Akcje
STATE STREET CORP $2 381 082 692 26 321 940 7,87% Akcje
WELLINGTON MANAGEMENT GROUP LLP $1 430 999 585 15 819 142 4,73% Akcje
GEODE CAPITAL MANAGEMENT, LLC $1 219 437 867 13 541 730 4,03% Akcje
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $1 135 640 991 12 554 068 3,75% Akcje
Ninety One UK Ltd $1 116 050 276 12 337 502 3,69% Akcje
Aristotle Capital Management, LLC $783 906 442 8 665 712 2,59% Akcje
NORGES BANK $757 492 410 8 373 783 2,50% Akcje
ALLIANCEBERNSTEIN L.P. $693 526 113 8 660 416 2,29% Akcje
FMR LLC $607 177 379 6 712 109 2,01% Akcje
Artisan Partners Limited Partnership $599 361 052 6 625 703 1,98% Akcje
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $513 572 538 5 677 344 1,70% Akcje
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST $434 208 000 4 800 000 1,44% Akcje
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $334 052 859 3 692 824 1,10% Akcje
MILLENNIUM MANAGEMENT LLC $324 280 556 3 584 795 1,07% Akcje
CITADEL ADVISORS LLC $308 338 066 3 408 557 1,02% Akcje
PRIMECAP MANAGEMENT CO/CA/ $308 314 004 3 408 291 1,02% Akcje
DIMENSIONAL FUND ADVISORS LP $298 865 427 3 303 843 0,99% Akcje
BROWN ADVISORY INC $295 062 880 3 261 805 0,98% Akcje
VANGUARD FIDUCIARY TRUST CO $292 399 738 3 232 365 0,97% Akcje
Holocene Advisors, LP $283 979 721 3 139 285 0,94% Akcje
NEUBERGER BERMAN GROUP LLC $255 069 412 2 818 763 0,84% Akcje
JACOBS LEVY EQUITY MANAGEMENT, INC $250 776 107 2 772 232 0,83% Akcje
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $238 277 000 2 634 054 0,79% Akcje
Mirova US LLC $229 802 865 2 540 381 0,76% Akcje
BANK OF AMERICA CORP /DE/ $170 884 489 1 889 061 0,56% Akcje
BlackRock, Inc. $168 018 323 1 857 377 0,56% Akcje
Assenagon Asset Management S.A. $163 997 286 1 812 926 0,54% Akcje
Point72 Asset Management, L.P. $160 486 895 1 774 120 0,53% Akcje
RAYMOND JAMES FINANCIAL INC $152 806 000 1 689 211 0,51% Akcje
Swiss National Bank $147 097 006 1 626 100 0,49% Akcje
Woodline Partners LP $141 123 209 1 560 062 0,47% Akcje
Universal- Beteiligungs- und Servicegesellschaft mbH $140 351 128 1 551 434 0,46% Akcje
TWO SIGMA INVESTMENTS, LP $137 670 984 1 521 899 0,46% Akcje
MANUFACTURERS LIFE INSURANCE COMPANY, THE $131 472 173 1 453 357 0,43% Akcje
Mitsubishi UFJ Asset Management Co., Ltd. $126 120 870 1 394 217 0,42% Akcje
Legal & General Group Plc $121 108 845 1 338 811 0,40% Akcje
ROYAL BANK OF CANADA $119 193 000 1 317 637 0,39% Akcje
Sumitomo Mitsui Trust Group, Inc. $113 885 341 1 258 958 0,38% Akcje
Quantinno Capital Management LP $113 292 795 1 252 407 0,37% Akcje
Vanguard Global Advisers, LLC $112 247 472 1 240 852 0,37% Akcje
Liontrust Investment Partners LLP $110 033 644 1 216 379 0,36% Akcje
VANGUARD GROUP INC $107 656 172 1 262 829 0,36% Akcje
SEB Asset Management AB $106 981 085 1 182 636 0,35% Akcje
VANGUARD ASSET MANAGEMENT, Ltd $100 522 409 1 111 236 0,33% Akcje
Polar Capital Holdings Plc $99 945 636 1 104 860 0,33% Akcje
RHUMBLINE ADVISERS $99 213 696 1 096 770 0,33% Akcje
BNP PARIBAS FINANCIAL MARKETS $92 822 996 1 026 122 0,31% Akcje
PARNASSUS INVESTMENTS, LLC $91 873 890 1 015 630 0,30% Akcje
Bank of New York Mellon Corp $91 654 072 1 013 200 0,30% Akcje
National Pension Service $90 349 187 998 775 0,30% Akcje
California Public Employees Retirement System $89 091 250 984 869 0,29% Akcje
Caisse de depot et placement du Quebec $87 523 397 967 537 0,29% Akcje
ABN AMRO Bank N.V. $83 573 385 924 314 0,28% Akcje
GOLDMAN SACHS GROUP INC $82 454 109 911 498 0,27% Akcje
Empower Advisory Group, LLC $80 384 543 888 620 0,27% Akcje
Meridiem Capital Partners LP $77 697 994 858 921 0,26% Akcje
Man Group plc $76 372 212 844 265 0,25% Akcje
ORBIMED ADVISORS LLC $75 525 054 834 900 0,25% Akcje
Alyeska Investment Group, L.P. $73 531 316 812 860 0,24% Akcje
Nantahala Capital Management, LLC $72 368 000 800 000 0,24% Opcja sprzedaży
CANADA PENSION PLAN INVESTMENT BOARD $72 254 020 798 740 0,24% Akcje
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $69 805 736 871 700 0,23% Akcje
ENVESTNET ASSET MANAGEMENT INC $66 940 606 740 002 0,22% Akcje
Bellevue Group AG $66 871 108 739 234 0,22% Akcje
Birch Hill Investment Advisors LLC $66 522 203 735 377 0,22% Akcje
ADAGE CAPITAL PARTNERS GP, L.L.C. $64 772 074 716 030 0,21% Akcje
TD Asset Management Inc $61 560 472 680 527 0,20% Akcje
PRINCIPAL FINANCIAL GROUP INC $61 491 904 679 769 0,20% Akcje
UBS Group AG $60 908 889 673 324 0,20% Akcje
Candriam S.C.A. $59 988 129 663 784 0,20% Akcje
VIRGINIA RETIREMENT SYSTEMS ET Al $57 604 363 675 711 0,19% Akcje
Integral Health Asset Management, LLC $56 537 500 625 000 0,19% Akcje
Ninety One North America, Inc. $55 768 413 616 498 0,18% Akcje
Robeco Institutional Asset Management B.V. $55 270 246 610 991 0,18% Akcje
Seilern Investment Management Ltd $54 296 896 600 231 0,18% Akcje
Nan Shan Life Insurance Co., Ltd. $49 953 912 552 221 0,17% Akcje
PFA Pension, Forsikringsaktieselskab $49 175 025 543 611 0,16% Akcje
BARCLAYS PLC $49 135 520 543 174 0,16% Akcje
Triodos Investment Management BV $44 629 165 493 358 0,15% Akcje
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $44 266 149 489 345 0,15% Akcje
Mitsubishi UFJ Trust & Banking Corp $43 182 890 477 370 0,14% Akcje
APG Asset Management N.V. $42 840 046 541 444 0,14% Akcje
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund $42 480 287 469 603 0,14% Akcje
Zurcher Kantonalbank (Zurich Cantonalbank) $42 097 461 465 371 0,14% Akcje
AVIVA PLC $41 577 497 459 623 0,14% Akcje
Balyasny Asset Management L.P. $41 248 584 455 987 0,14% Akcje
Korea Investment CORP $40 486 097 447 558 0,13% Akcje
SUSQUEHANNA INTERNATIONAL GROUP, LLP $39 585 296 437 600 0,13% Opcja kupna
NORDEA INVESTMENT MANAGEMENT AB $37 761 927 418 322 0,12% Akcje
STOREBRAND ASSET MANAGEMENT AS $37 671 343 416 442 0,12% Akcje
Qube Research & Technologies Ltd $37 490 061 414 438 0,12% Akcje
OFI INVEST ASSET MANAGEMENT $36 480 086 458 427 0,12% Akcje
Fisher Funds Management LTD $35 971 057 397 646 0,12% Akcje
LPL Financial LLC $34 985 891 386 755 0,12% Akcje
ABN AMRO INVESTMENT SOLUTIONS $33 668 217 372 189 0,11% Akcje
AMERIPRISE FINANCIAL INC $32 517 021 359 463 0,11% Akcje
BLAIR WILLIAM & CO/IL $32 206 687 356 032 0,11% Akcje
Champlain Investment Partners, LLC $31 357 054 346 640 0,10% Akcje

Insiderzy spółki 48 insiderów · 18 dyrektorzy generalni · 8 dyrektorzy

Insider Rola Ostatnia aktywność Posiadane akcje Kupna 12m Sprzedaże 12m Netto 12m
Bernard J Zovighian CEO 27 lipca 2026 S 8 916 0 8 $-6 996 971
Theodora Mistras CVP, Chief Financial Officer 9 lipca 2026 A 99 920 0 0 $0
Thomas M Abate CVP, CFO 14 maja 2013 A 43 047 0 0 $0
Wayne Markowitz CVP, JAPAC 30 lipca 2026 S 21 534 0 4 $-928 942
Annette Bruls CVP, EMEACLA 11 lipca 2026 F 20 628 0 0 $0
Andrew M. Dahl SVP, Corporate Controller 29 maja 2026 S 15 334 0 1 $-48 893
Carlyn D Solomon CVP, Critical Care & Vascular 28 października 2014 M 31 154 0 0 $0
Christine Z Mccauley CVP, Human Resources 13 maja 2013 F 4 035 0 0 $0
Paul C Redmond CVP, Global Operations 13 maja 2013 S 12 534 0 0 $0
Bruce P Garren CVP, Public Affairs/Special Co 13 maja 2013 F 56 071 0 0 $0
John H Kehl JR CVP, Strategy & Corp Dev 7 maja 2013 F 101 767 0 0 $0
Robert C Reindl CVP, H.R. and Communications 27 lipca 2012 M 1 124 0 0 $0
Aimee S Weisner CVP, General Counsel 9 maja 2012 A 1 675 0 0 $0
Corinne H Nevinny CVP & Pres., Global Ops 13 maja 2010 A 16 687 0 0 $0
Anita Bessler CVP 31 sierpnia 2007 S 29 410 0 0 $0
John Alexander Martin CVP, North America 10 maja 2007 A 15 300 0 0 $0
Stuart L Foster CVP, Critical Care / Vascular 10 maja 2007 A 24 604 0 0 $0
Randel William Woodgrift Corp VP, Manufacturing Ops 4 sierpnia 2005 M 3 349 0 0 $0
John T Cardis Dyrektor 10 sierpnia 2016 S 91 458 0 0 $0
Barbara J Mcneil Dyrektor 4 lutego 2016 S 46 454 0 0 $0
Robert Alexander Ingram Dyrektor 15 maja 2015 A 32 367 0 0 $0
Michael R Bowlin Dyrektor 14 listopada 2014 M 81 751 0 0 $0
David E I Pyott Dyrektor 9 maja 2014 A 53 582 0 0 $0
NEAL PHILIP M Dyrektor 12 sierpnia 2008 M 27 333 0 0 $0
Vernon R Loucks JR Dyrektor 9 maja 2008 A 24 133 0 0 $0
Daniel J. Lippis — 11 sierpnia 2026 M 40 034 0 12 $-817 452
Donald E Bobo JR — 27 maja 2026 S 98 611 0 12 $-11 153 294
Daveen Chopra — 22 maja 2026 S 44 324 0 3 $-500 535
Scott B. Ullem — 11 maja 2026 M 46 740 0 7 $-3 875 008
Leslie C. Davis — 8 maja 2026 A 9 834 0 0 $0
Ramona Sequeira — 8 maja 2026 A 6 779 0 0 $0
David T Feinberg — 8 maja 2026 A 9 087 0 0 $0
Kieran Gallahue — 8 maja 2026 A 4 315 0 0 $0
Nicholas J Valeriani — 8 maja 2026 A 84 423 0 0 $0
Heisz Leslie Stone — 8 maja 2026 A 34 199 0 1 $-218 117
Steven R Loranger — 8 maja 2026 A 8 997 0 0 $0
Paul A Laviolette — 8 maja 2026 A 17 552 0 0 $0
Larry L Wood — 18 sierpnia 2025 M 206 900 0 0 $0
Catherine M. Szyman — 3 września 2024 F 81 287 0 0 $0
Jean-Luc M Lemercier — 7 lipca 2024 F 184 686 0 0 $0
Robert W.A. Sellers — 11 maja 2024 F 17 081 0 0 $0
Michael A Mussallem — 2 maja 2024 M 4 486 0 0 $0
Martha H. Marsh — 12 maja 2023 A 31 880 0 0 $0
Huimin Wang — 8 lipca 2022 M 99 381 0 0 $0
William J Link PHD — 8 maja 2020 A 11 349 0 0 $0
Wesley W Von Schack — 1 sierpnia 2019 S 8 000 0 0 $0
Patrick B Verguet — 31 maja 2017 M 129 137 0 0 $0
Randall J Nelson — 30 września 2003 A — 0 0 $0

Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S

Aktywiści i właściciele 5%+ 1 akcja

Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.

Zgłaszający Złożono Udział Status Cel Zgłoszenie
Niezgłoszona osoba raportująca 5 kwietnia 2001 — Pierwotne zgłoszenie Kampania zarządu SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Posiadanie ETF-ów Posiadane przez 181 funduszy ETF

Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.

Fundusz Waga Jednostki Na dzień Źródło
GDOC · Goldman Sachs ETF Trust 2,98% 6 939 NS 31 maja 2026 N-PORT
FMED · Fidelity Covington Trust 2,11% 10 000 NS 31 maja 2026 N-PORT
WBIL · Absolute Shares Trust 2,04% 6 865 NS 30 czerwca 2026 N-PORT
ANEW · ProShares Trust 2,02% 1 801 NS 31 maja 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 1,83% 2 435 NS 30 kwietnia 2026 N-PORT
PJBF · PGIM ETF Trust 1,75% 2 374 NS 29 maja 2026 N-PORT
HRTS · Tema ETF Trust 1,75% 10 488 NS 31 maja 2026 N-PORT
ALTL · Pacer Funds Trust 0,94% 10 780 NS 30 kwietnia 2026 N-PORT
CVAR · ETF Opportunities Trust 0,93% 4 325 NS 30 kwietnia 2026 N-PORT
FFND · Northern Lights Fund Trust II 0,88% 10 459 NS 31 maja 2026 N-PORT
BKDV · BNY Mellon ETF Trust II 0,81% 134 666 NS 30 kwietnia 2026 N-PORT
PRAY · FIS Trust 0,80% 7 525 NS 31 maja 2026 N-PORT
NULV · Nushares ETF Trust 0,79% 197 378 NS 30 kwietnia 2026 N-PORT
JOET · Virtus ETF Trust II 0,79% 22 410 NS 30 kwietnia 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0,78% 267 514 NS 30 kwietnia 2026 N-PORT
NULC · Nushares ETF Trust 0,75% 5 090 NS 30 kwietnia 2026 N-PORT
RXL · ProShares Trust 0,73% 6 052 NS 31 maja 2026 N-PORT
CURE · Direxion Shares ETF Trust 0,70% 11 571 NS 30 kwietnia 2026 N-PORT
TEC · Harbor ETF Trust 0,61% 491 NS 30 kwietnia 2026 N-PORT
FWD · AB Active ETFs, Inc. 0,56% 187 544 NS 31 maja 2026 N-PORT
HUSV · First Trust Exchange-Traded Fund III 0,56% 4 857 NS 30 kwietnia 2026 N-PORT
BRNY · EA Series Trust 0,54% 35 555 NS 30 kwietnia 2026 N-PORT
AVMC · AMERICAN CENTURY ETF TRUST 0,53% 24 654 NS 31 maja 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0,42% 44 305 NS 30 kwietnia 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,40% 193 493 NS 30 kwietnia 2026 N-PORT
JOYT · J.P. Morgan Exchange-Traded Fund Tr… 0,37% 3 768 NS 30 kwietnia 2026 N-PORT
JGLO · J.P. Morgan Exchange-Traded Fund Tr… 0,34% 286 558 NS 30 kwietnia 2026 N-PORT
NBCR · Neuberger Berman ETF Trust 0,30% 30 404 NS 31 maja 2026 N-PORT
ESUM · Strategy Shares 0,27% 5 033 NS 30 kwietnia 2026 N-PORT
DFLV · Dimensional ETF Trust 0,27% 189 108 NS 30 kwietnia 2026 N-PORT
WINN · Harbor ETF Trust 0,24% 31 226 NS 30 kwietnia 2026 N-PORT
DEUS · DBX ETF Trust 0,24% 7 428 NS 29 maja 2026 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr… 0,23% 887 NS 30 kwietnia 2026 N-PORT
FFLG · FIDELITY COVINGTON TRUST 0,22% 15 544 NS 30 kwietnia 2026 N-PORT
GSEW · Goldman Sachs ETF Trust 0,21% 42 168 NS 31 maja 2026 N-PORT
GINN · Goldman Sachs ETF Trust 0,19% 4 761 NS 31 maja 2026 N-PORT
DFUV · Dimensional ETF Trust 0,19% 327 013 NS 30 kwietnia 2026 N-PORT
SNPG · DBX ETF Trust 0,18% 287 NS 29 maja 2026 N-PORT
FTLS · First Trust Exchange-Traded Fund III 0,17% 46 447 NS 30 kwietnia 2026 N-PORT
OALC · Unified Series Trust 0,17% 4 706 NS 31 maja 2026 N-PORT
SCHV · SCHWAB STRATEGIC TRUST 0,16% 292 449 NS 31 maja 2026 N-PORT
FTC · First Trust Exchange-Traded AlphaDE… 0,16% 24 546 NS 30 kwietnia 2026 N-PORT
IQSU · New York Life Investments ETF Trust 0,16% 5 945 NS 30 kwietnia 2026 N-PORT
ESLV · Strategy Shares 0,16% 220 NS 30 kwietnia 2026 N-PORT
USSG · DBX ETF Trust 0,15% 9 901 NS 29 maja 2026 N-PORT
USNZ · DBX ETF Trust 0,15% 5 178 NS 29 maja 2026 N-PORT
GVUS · Goldman Sachs ETF Trust 0,15% 6 924 NS 31 maja 2026 N-PORT
HLAL · Listed Funds Trust 0,14% 14 853 NS 31 maja 2026 N-PORT
SPUS · Tidal Trust I 0,13% 42 149 NS 31 maja 2026 N-PORT
HAPI · Harbor ETF Trust 0,13% 7 528 NS 30 kwietnia 2026 N-PORT